QS-21
- Generic Name
- QS-21
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 61H83WZX3U
- Background
QS-21 is an investigational adjuvant, which is a substance added to vaccines and other immunotherapies that is designed to enhance the body’s immune response to the antigen contained within the treatment. It is the leading member of the Stimulon family of adjuvants. As a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.
- Indication
Investigated for use/treatment in genital herpes, HIV infection, hepatitis (viral, B), influenza, malaria, melanoma, and viral infection.
BZLF1 Peptide Vaccine (OSU-2131) with QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants
- Conditions
- Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative DisorderEBV-Related Malignant NeoplasmPost-Transplant Lymphoproliferative Disorder
- Interventions
- Procedure: Biospecimen CollectionDrug: Dulbecco''s Phosphate-Buffered Saline
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Target Recruit Count
- 55
- Registration Number
- NCT06741072
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer
- Conditions
- Pancreas Cancer
- Interventions
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05638698
- Locations
- 🇺🇸
University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
🇺🇸University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
🇺🇸University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01687595
- Locations
- 🇺🇸
Center for Clinical Studies - Cypress, Houston, Texas, United States
🇺🇸Westover Heights Clinic, Portland, Oregon, United States
🇺🇸Center for Clinical Studies - Texas Medical Center, Houston, Texas, United States
Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype
- Conditions
- B Cell LymphomaNeoplasmFollicular Lymphoma
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT00001572
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.